Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3ITD AML with Secondary Acquired Mutations

被引：3

作者：

Yamatani, Kotoko ^{[1
]}

Tabe, Yoko ^{[2
,3
,4
]}

Saito, Kaori ^{[1
]}

Yang, Haeun ^{[1
,5
]}

Murakami-Tonami, Yuko ^{[1
]}

Suzuki, Koya ^{[1
,6
]}

Zhang, Weiguo ^{[7
]}

Kinjo, Sonoko ^{[8
]}

Ikeo, Kazuho ^{[8
]}

Mogushi, Kaoru ^{[9
,10
]}

Hosoya, Masaki ^{[10
,11
]}

Yamaguchi, Shigeo ^{[11
]}

Harada, Hironori ^{[12
]}

Miida, Takashi ^{[1
]}

Shah, Neil P. ^{[13
]}

Konopleva, Marina Y. ^{[14
]}

Hayashizaki, Yoshihide ^{[15
]}

Andreeff, Michael ^{[14
]}

机构：

[1] Juntendo Univ, Grad Sch Med, Dept Clin Lab Med, Tokyo, Japan

[2] Juntendo Univ, Dept Clin Lab Med, Sch Med, Tokyo, Japan

[3] Juntendo Univ, Grad Sch Medcine, Dept Next Generat Hematol Lab Med, Tokyo, Japan

[4] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA

[5] Juntendo Univ, Grad Sch Med, Leading Ctr Dev & Res Canc Med, Tokyo, Japan

[6] Juntendo Univ, Res Inst Dis Old Age, Grad Sch Med, Tokyo, Japan

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Natl Inst Genet, Ctr Informat Biol, Shizuoka, Japan

[9] Juntendo Univ, Grad Sch Med, Dept Diagnost & Therapeut Intractable Dis, Tokyo, Japan

[10] Juntendo Univ, Grad Sch Med, Intractable Dis Res Ctr, Tokyo, Japan

[11] Juntendo Univ, Sch Med, Dept Oncol, Tokyo, Japan

[12] Juntendo Univ, Grad Sch Med, Dept Hematol, Tokyo, Japan

[13] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Leukemia Biol Res, Houston, TX 77030 USA

[15] RIKEN, Ctr Life Sci Technoligies, Prevent Med & Diag Innovat Program, Yokohama, Kanagawa, Japan

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-109957

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3944

引用

页数：2

共 50 条

[21] Mutations in c-kit are as common as flt3/ITD mutations in pediatric AML
Goemans, BF
Zwaan, CM
Miller, M
Hahlen, K
Meshinchi, S
Reinhardt, D
Creutzig, U
Kaspers, GJL
Heinrich, MC
LEUKEMIA, 2003, 17 (03) : 675 - 675
[22] Concealed dagger in FLT3/ITD+ AML
Ofran, Yishai
BLOOD, 2014, 124 (15) : 2317 - 2319
[23] CRENOLANIB IS EFFECTIVE AGAINST SECONDARY FLT3 MUTATIONS IN AML
不详
CANCER DISCOVERY, 2013, 3 (11) : 1215 - 1215
[24] FLT3/ITD AML and the law of unintended consequences
Levis, Mark
BLOOD, 2011, 117 (26) : 6987 - 6990
[25] SCT ameliorates the effects of FLT3–ITD in AML
Peter Sidaway
Nature Reviews Clinical Oncology, 2016, 13 (2) : 64 - 64
[26] FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML
Weisberg, Ellen
Barrett, Rosemary
Liu, Qingsong
Stone, Richard
Gray, Nathanael
Griffin, James D.
DRUG RESISTANCE UPDATES, 2009, 12 (03) : 81 - 89
[27] FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations.
Minden, M. D.
Kornblau, Steven M.
Rosen, David B.
Cohen, Aileen Cleary
Gayko, Urte
Putta, Santosh
Woronicz, John
Fantl, Wendy J.
Cesano, Alessandra
BLOOD, 2009, 114 (22) : 635 - 635
[28] Mechanisms of FLT3 inhibitor resistance by FLT3 double mutations
Katayama, Kazuhiro
CANCER SCIENCE, 2025, 116 : 1554 - 1554
[29] Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition
Dzama, Margarita M.
Steiner, Marlene
Rausch, Johanna
Sasca, Daniel
Schoenfeld, Jonas
Kunz, Kerstin
Taubert, Martha C.
McGeehan, Gerard M.
Chen, Chun-Wei
Mupo, Annalisa
Haehnel, Patricia
Theobald, Matthias
Kindler, Thomas
Koche, Richard P.
Vassiliou, George S.
Armstrong, Scott A.
Kuehn, Michael W. M.
BLOOD, 2020, 136 (21) : 2442 - 2456
[30] Therapeutic targeting of FLT3 mutations in AML via menin-MLL1 and FLT3 inhibition
Dzama, Margarita M.
Taubert, Martha C.
Kunz, Kerstin
Rausch, Johanna
Chen, Chun-Wei
Mupo, Annalisa
Theobald, Matthias
Kindler, Thomas
Koche, Richard P.
Vassiliou, George S.
Armstrong, Scott A.
Kuehn, Michael W.
CANCER RESEARCH, 2019, 79 (13)

← 1 2 3 4 5 →